Aytu BioPharma, Inc. (0A8M.L)

2.8700 +0.0683 (+2.44%) As of 05:47PM BST. Market open.

Aytu BioPharma, Inc.

Denver Corporate Center III
7900 East Union Avenue Suite 920
Denver, CO 80237
United States
720 437 6580
https://aytubio.com

Sector(s): 
Industry: 
Full-time employees: 150

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Joshua R. Disbrow	Chairman & CEO	708k	N/A	1975
Mr. Mark K. Oki CPA	CFO, Secretary & Treasurer	522.84k	N/A	1969
Mr. Greg Pyszczymuka	Chief Commercial Officer	525k	N/A	1979
Ms. Victoria Cordova	Vice President of People & Culture	N/A	N/A	N/A
Mr. Jarrett T. Disbrow Ph.D.	Chief Business Officer & President of Consumer Health	355k	N/A	1975
Mr. Russ McMahen	Senior Vice President of Research & Development	N/A	N/A	N/A
Mr. Ryan J. Selhorn CPA	Executive VP of Finance & Business Optimization	N/A	N/A	1982

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

Corporate governance

Aytu BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.